Skip to main content
. 2022 Oct 15;1(6):100509. doi: 10.1016/j.jscai.2022.100509

Table 2.

Procedural characteristics with composite outcome (N = 795)

Procedure variables Men (n = 448) Women (n = 347)
TAVR type: balloon expandable valve 163 (36.5) 140 (40.2)
TAVR size, mm 27.36 ± 2.99 25.10 ± 2.42
Access
 Transfemoral 425 (95.1) 337 (96.8)
 Transapical 17 (3.8) 10 (2.9)
 Trans-subclavian 2 (0.4) 1 (0.3)
 Transaortic 3 (0.7) 0 (0.0)
Acute procedural success 444 (99.3) 342 (98.3)
PCI, before and after 79 (17.7) 41 (11.8)
Bleeding
 No 338 (75.6) 248 (71.3)
 Minor 9 (2.0) 174 (50.0)
 Major 20 (4.5) 13 (3.7)
 Life threatening 80 (17.9) 12 (3.4)
Mean gradient after TAVR, mm Hg 9.61 ± 4.88 10.96 ± 5.98
Mean gradient after TAVR
 <10 mm Hg 248 (57.0) 154 (45.7)
 10-20 mm Hg 174 (40.0) 164 (48.7)
 >20 mm Hg 13 (3.0) 19 (5.6)
Paravalvular leak
 No 310 (69.4) 261 (75.0)
 Mild 112 (25.1) 73 (21.0)
 Moderate to severe 25 (5.6) 14 (4.0)
Balloon dilation, before or after 83 (18.6) 59 (17.05)
PPM 60 (13.4) 35 (10.1)
Post-TAVR CVA 7 (1.6) 4 (1.1)
Post-TAVR MI (clinically relevant) 2 (0.4) 3 (0.9)
Post-TAVR death 11 (2.5) 9 (2.6)
General Anesthesia 128 (28.6) 115 (33.0)
Complication
 None 418 (93.5) 322 (92.5)
 Coronary obstruction 4 (0.9) 5 (1.4)
 Rupture 0 (0.0) 2 (0.6)
 Embolization 4 (0.9) 4 (1.1)
 Other 21 (4.7) 15 (4.3)
 Emergency surgery 6 (1.3) 5 (1.4)

Values are mean ± SD or n (%).

CVA, cerebrovascular accident; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; TAVR, transcatheter aortic valve replacement.